← Back to Search

Virus Therapy

ICU Cohort for COVID-19

Phase 2
Waitlist Available
Led By Mary Beth Graham
Research Sponsored by Medical College of Wisconsin
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up length of admission in the icu for covid through study follow-up period
Awards & highlights

Study Summary

This trial is testing if using plasma from people who have recovered from COVID-19 can help treat people who are currently sick with the disease.

Eligible Conditions
  • COVID-19
  • Coronavirus

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~duration of patient hospitalization, sometimes exceeding 60 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and duration of patient hospitalization, sometimes exceeding 60 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Overall Mortality
Secondary outcome measures
Length of Admission After Plasma Infusion
Length of ICU Stay After Convalescent Plasma Infusion

Side effects data

From 2021 Phase 2 trial • 131 Patients • NCT04354831
27%
Intubation
10%
Bacteremia
100%
80%
60%
40%
20%
0%
Study treatment Arm
ICU Cohort
Non-ICU Cohort

Trial Design

2Treatment groups
Experimental Treatment
Group I: Non-ICU CohortExperimental Treatment1 Intervention
Patients who are NOT in the ICU at the time of enrollment. Patients will receive anti-SARS-CoV-2 convalescent plasma.
Group II: ICU CohortExperimental Treatment1 Intervention
Patients who are in the ICU at the time of enrollment. Patients will receive anti-SARS-CoV-2 convalescent plasma.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
anti-SARS-CoV-2 convalescent plasma
2020
Completed Phase 2
~350

Find a Location

Who is running the clinical trial?

Medical College of WisconsinLead Sponsor
608 Previous Clinical Trials
1,162,370 Total Patients Enrolled
6 Trials studying COVID-19
482 Patients Enrolled for COVID-19
Froedtert HospitalOTHER
9 Previous Clinical Trials
10,585 Total Patients Enrolled
Mary Beth GrahamPrincipal InvestigatorMedical College of Wisconsin

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Efficacy and Safety of Convalescent Plasma in Treating COVID-19 Hospitalized Patients
Mary Beth Graham, MD 2020. "Efficacy and Safety of Convalescent Plasma in Treating COVID-19 Hospitalized Patients". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04354831.
~27 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top